Table 1.
Patient demographics by first-line treatment n (%)
|
First-line treatment |
All newly treated patients | |||||||||
| SSA | CC | TT | SSA + CC | SSA + TT | TT + CC | IF | SSA + IF | SSA + TT + CC | ||
| n | 13451 | 752 | 81 | 42 | 31 | 3 | 2 | 1 | 1 | 2258 |
| 59.6% | 33.3% | 3.6% | 1.9% | 1.4% | 0.1% | 0.1% | 0.0 | 0.0 | 100.0% | |
| Age (mean ± SD, yr) | 56.3 ± 9.5 | 54.7 ± 9.9 | 54.9 ± 10.5 | 53.5 ± 10.9 | 53.8 ± 10.1 | 59.3 ± 3.8 | 58.5 ± 3.5 | N/A | N/A | 55.6 ± 9.7 |
| 18-24 | 6 (0.4) | 2 (0.3) | 0 (0) | 1 (2.4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 9 (0.4) |
| 25-34 | 20 (1.5) | 25 (3.3) | 4 (4.9) | 3 (7.1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 52 (2.3) |
| 35-44 | 121 (9.0) | 92 (12.2) | 9 (11.1) | 4 (9.5) | 4 (12.9) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 230 (10.2) |
| 45-54 | 371 (27.6) | 225 (29.9) | 18 (22.2) | 12 (28.6) | 12 (38.7) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 638 (28.3) |
| 55-64 | 651 (48.4) | 338 (44.9) | 39 (48.1) | 20 (47.6) | 11 (35.5) | 3 (100.0) | 2 (100.0) | 1 (100.0) | 1 (100.0) | 1066 (47.2) |
| 65+ | 176 (13.1) | 70 (9.3) | 11 (13.6) | 2 (4.8) | 4 (12.9) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 263 (11.6) |
| Female | 677 (50.3) | 341 (45.3) | 40 (49.4) | 26 (61.9) | 17 (54.8) | 1 (33.3) | 1 (50.0) | 0 (0.0) | 0 (0.0) | 1103 (48.8) |
| Region | ||||||||||
| Midwest | 321 (23.9) | 183 (24.3) | 20 (24.7) | 13 (31.0) | 7 (22.6) | 0 (0) | 1 (50.0) | 0 (0) | 0 (0) | 545 (24.1) |
| Northeast | 261 (19.4) | 150 (19.9) | 12 (14.8) | 11 (26.2) | 7 (22.6) | 1 (33.3) | 0 (0) | 0 (0) | 0 (0) | 442 (19.6) |
| South | 563 (41.9) | 323 (43.0) | 36 (44.4) | 12 (28.6) | 15 (48.4) | 2 (66.7) | 1 (50.0) | 0 (0) | 1 (100.0) | 953 (42.2) |
| West | 200 (14.9) | 96 (12.8) | 13 (16.0) | 6 (14.3) | 2 (6.5) | 0 (0) | 0 (0) | 1 (100.0) | 0 (0) | 318 (14.1) |
| Year of treatment initiation | 130 (9.7) | 41 (5.5) | 4 (4.9) | 2 (4.8) | 1 (3.2) | 0 (0) | 0 (0) | 1 (100.0) | 0 (0) | 179 (7.9) |
| 2009 | ||||||||||
| 2010 | 271 (20.1) | 122 (16.2) | 4 (4.9) | 11 (26.2) | 7 (22.6) | 0 (0) | 1 (50.0) | 0 (0) | 0 (0) | 416 (18.4) |
| 2011 | 282 (21.0) | 159 (21.1) | 15 (18.5) | 17 (40.5) | 5 (16.1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 478 (21.2) |
| 2012 | 270 (20.1) | 168 (22.3) | 33 (40.7) | 4 (9.5) | 10 (32.3) | 0 (0) | 1 (50.0) | 0 (0) | 1 (100.0) | 487 (21.6) |
| 2013 | 268 (19.9) | 174 (23.1) | 16 (19.8) | 3 (7.1) | 4 (12.9) | 2 (66.7) | 0 (0) | 0 (0) | 0 (0) | 467 (20.7) |
| 2014 | 124 (9.2) | 88 (11.7) | 9 (11.1) | 5 (11.9) | 4 (12.9) | 1 (33.3) | 0 (0) | 0 (0) | 0 (0) | 231 (10.2) |
| Days of follow-up | ||||||||||
| Mean | 621 | 514 | 454 | 588 | 425 | 244 | 675 | 836 | 496 | 576 |
| (SD) | (468.5) | (409.1) | (403.6) | (424.1) | (269.6) | (140.7) | (145.7) | N/A | N/A | (447.1) |
| Median | 500 | 393 | 290 | 455 | 360 | 216 | 675 | 836 | 496 | 454 |
1
964 with octreotide LAR, 380 with octreotide SA, and 1 with lanreotide. SSA: Somatostatin analogues; CC: Cytotoxic chemotherapy; TT: Targeted therapy; IF: Interferon.